Skip to main content

Want a detailed portfolio tracker?

Mangoceuticals (MGRX) Income Statement (2022 - 2026)

Income Statement report data from Mar 31, 2022 to Mar 31, 2026 for Mangoceuticals (MGRX).

All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.

Reported currency: USD
Mar 31, 2026Sep 30, 2025Jun 30, 2025Mar 31, 2025Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022
Revenue and COGS
Total Revenue
70K
(-12.50%)
80K
(-52.94%)
170K
(+54.55%)
110K
(-15.38%)
130K
(-18.75%)
160K
(-23.81%)
210K
(-12.50%)
240K
(-4.00%)
250K
(+78.57%)
140K
(+40.00%)
100K
(+900.00%)
10K---
Cost Of Revenue
10K-20K
(0.00%)
20K
(0.00%)
20K
(-33.33%)
30K
(+50.00%)
20K
(-60.00%)
50K
(0.00%)
50K
(+66.67%)
30K
(+50.00%)
20K----
Costof Goods And Services Sold
10K-20K
(0.00%)
20K
(0.00%)
20K
(-33.33%)
30K
(+50.00%)
20K
(-60.00%)
50K
(0.00%)
50K
(+66.67%)
30K
(+50.00%)
20K----
Gross Profit
30K
(-40.00%)
50K
(-44.44%)
90K
(+50.00%)
60K
(-25.00%)
80K
(+14.29%)
70K
(-53.33%)
150K
(+7.14%)
140K
(0.00%)
140K
(+55.56%)
90K
(+50.00%)
60K----
Operating Expenses
Selling General And Administrative
1.05M
(+238.71%)
310K
(-75.20%)
1.25M
(-18.83%)
1.54M
(+196.15%)
520K
(-38.82%)
850K
(+10.39%)
770K
(-62.98%)
2.08M
(+285.19%)
540K
(-5.26%)
570K
(+338.46%)
130K
(-58.06%)
310K
(-68.69%)
990K
(+200.00%)
330K
(+1550.00%)
20K
Operating Expenses
3.16M
(-58.37%)
7.59M
(+41.60%)
5.36M
(+15.52%)
4.64M
(+152.17%)
1.84M
(-17.86%)
2.24M
(-11.11%)
2.52M
(-7.01%)
2.71M
(+39.69%)
1.94M
(-18.49%)
2.38M
(-9.16%)
2.62M
(+296.97%)
660K
(-33.33%)
990K
(+200.00%)
330K
(+1550.00%)
20K
Depreciation And Amortization
------10K
(-50.00%)
20K--10K----
Operating Income
Operating Income
-3.13M
(-58.49%)
-7.54M
(+43.07%)
-5.27M
(+15.07%)
-4.58M
(+160.23%)
-1.76M
(-18.89%)
-2.17M
(-8.44%)
-2.37M
(-7.78%)
-2.57M
(+42.78%)
-1.80M
(-21.40%)
-2.29M
(-10.55%)
-2.56M
(+293.85%)
-650.00K
(-34.34%)
-990.00K
(+200.00%)
-330.00K
(+1550.00%)
-20.00K
Ebit
-3.13M
(-58.49%)
-7.54M
(+43.07%)
-5.27M
(+15.07%)
-4.58M
(+160.23%)
-1.76M
(-18.89%)
-2.17M
(-8.44%)
-2.37M
(-7.78%)
-2.57M
(+42.78%)
-1.80M
(-21.40%)
-2.29M
(-10.55%)
-2.56M
(+293.85%)
-650.00K
(-34.34%)
-990.00K
(+200.00%)
-330.00K
(+1550.00%)
-20.00K
EBITDA
-3.13M
(-58.49%)
-7.54M
(+39.89%)
-5.39M
(+17.69%)
-4.58M
(+129.00%)
-2.00M
(-16.32%)
-2.39M
(+1.27%)
-2.36M
(-7.81%)
-2.56M
(+42.22%)
-1.80M
(-21.05%)
-2.28M
(-10.59%)
-2.55M
(+286.36%)
-660.00K
(-33.33%)
-990.00K
(+219.35%)
-310.00K
(+1450.00%)
-20.00K
Other Income / Expenses
Interest Expense
-80K
(+300.00%)
20K-10.00K----10.00K---10K---
Net Interest Income
-------10K----10.00K---
Other Non Operating Income
-280.00K
(+250.00%)
-80.00K
(-46.67%)
-150.00K
(-42.31%)
-260.00K
(+8.33%)
-240.00K
(+9.09%)
-220.00K-10K-10K--10.00K---
Net Income
Income Before Tax
-3.40M
(-55.38%)
-7.62M
(+40.59%)
-5.42M
(+11.98%)
-4.84M
(+142.00%)
-2.00M
(-16.32%)
-2.39M
(+0.84%)
-2.37M
(-7.78%)
-2.57M
(+42.78%)
-1.80M
(-21.05%)
-2.28M
(-10.94%)
-2.56M
(+293.85%)
-650.00K
(-34.34%)
-990.00K
(+200.00%)
-330.00K
(+1550.00%)
-20.00K
Net Income From Continuing Operations
-3.40M
(-55.38%)
-7.62M
(+40.59%)
-5.42M
(+11.98%)
-4.84M
(+142.00%)
-2.00M
(-16.32%)
-2.39M
(+0.84%)
-2.37M
(-7.78%)
-2.57M
(+42.78%)
-1.80M
(-21.05%)
-2.28M
(-10.94%)
-2.56M
(+282.09%)
-670.00K
(-32.32%)
-990.00K
(+219.35%)
-310.00K
(+1450.00%)
-20.00K
Net Income
-3.40M
(-55.38%)
-7.62M
(+40.59%)
-5.42M
(+11.98%)
-4.84M
(+142.00%)
-2.00M
(-16.32%)
-2.39M
(+0.84%)
-2.37M
(-7.78%)
-2.57M
(+42.78%)
-1.80M
(-21.05%)
-2.28M
(-10.94%)
-2.56M
(+282.09%)
-670.00K
(-32.32%)
-990.00K
(+219.35%)
-310.00K
(+1450.00%)
-20.00K
Comprehensive Income Net Of Tax
-3.40M
(-55.38%)
-7.62M
(+40.59%)
-5.42M
(+12.22%)
-4.83M
(+141.50%)
-2.00M
(-16.32%)
-2.39M
(+0.84%)
-2.37M
(-74.27%)
-9.21M
(+411.67%)
-1.80M
(-21.05%)
-2.28M
(-10.94%)
-2.56M----